Myhep and Mydekla 12 Weeks Mylan Tablets Uses, MRP, Price india.

1. Myhep and Mydekla 12 Weeks Mylan Tablets Uses, MRP, Price india Myhep-Mydekla |Myhep-Mydekla tablet |Myhep-Mydekla price in india Drug profile Myhep-Mydekla tablets are anti-viral medication, containing two most predominant ingredients such as Sofosbuvir andDaclatasvir Myhep-Mydekla tablets are single dose therapy, it is a prescription medicine used by the patients only under the knowledge of medical practitioner who are well practiced Mydekla tablet is not used alone, for better action it should be combined with Myhep tablet. In some condition Myhep-Mydekla is combined with ribavirin, an anti-viral medicine used in decompensated (Child Pugh B or C) cirrhosis

2. Myhep Mydekla Myhep Mydekla Brand name: Myhep Mydekla Active components: Myhep-Sofosbuvir, Mydekla- Daclatasvir Strength of the components: 400mg & 60mg respectively Mfg: Mylan pharmaceuticals Package: 28 tablets in a container Category: Anti-viral drug price :Myhep-Mydekla price in india

3. Prescribing information for Myhep Mydekla The main indication of Myhep-Mydekla is; This combination tablets are used to treat the chronic hepatitis C viral infection caused by genotype I or III The major limitation occurred while using Myhep-Mydekla tablet tablets are reduction of constant virological response rate in hepatitis C genotype I or III infected patients. Mechanism of Myhep Mydekla The activity of Myhep-Mydekla tablet are occurred by involving in some mechanism; Myhep: Myhep containing sofosbuvir has anti-hepaciviral activity, which is directly acting drug exhibits its action by prohibiting NS5B RNA reliant RNA polymerase enzyme; essential for hepatitis viral multiplication. Sofosbuvir is metabolized to form uridine triphosphate, an essential active metabolite which exposes an anti-viral activity. The infusion of this active metabolite into hepatitis viral RNA with the help of NS5B polymerase and causes viral chain discontinuation Mydekla:

4. Mydekla containing Daclatasvir expels anti-viral activity by prohibiting NS5A protein which is needful in viral production and virion accumulation Absorption The peak plasma concentration of Mydekla tablets occurs within the range of 2 hours The absolute bioavailability of Mydekla is 67% The peak plasma concentration of Myhep tablets occurs within the range of 0.5 to 2 hours approximately. The food will not creates any variation in absorption of Myhep- Mydeklatablets, may be taken with or without food Distribution The volume of distribution in Mydekla tablet is 47L The human plasma protein bound with Mydekla tablet is nearly 99% The blood to plasma ratio of Myhep is relatively 0.7 The human plasma protein bound with Myhep occurs nearly 61 to 65% Metabolism

5. Myhep is metabolized hepatically and formed as pharmacologically active metabolite uridine triphosphate, metabolism undergone with the help of cathepsin A or carboxylesterase 1 Mydekla metabolism occurred with the help of CYP3A4 Elimination 88% of Daclatasvir is excreted through feces 53% as an unchanged form, 6.6% excreted through urine. The terminal half life period of Daclatasvir is occurred at 12 to 15 hours Sofosbuvir metabolites are excreted through 80% in urine, 14% in feces & 2.5% in exhaled air The terminal half life period of sofosbuvir is nearly 0.51 hours How to take the Tablet Myhep Mydekla Myhep-Mydekla tablet are administered with or without food, in the condition of hepatitis C viral infection originated by genotype I or III Myhep-Mydekla tablet is single dose regimen Dosage regimens Generally Daclatasvir is not used alone, it is combined with sofosbuvir

6. The recommended dosage of Myhep-Mydekla tablet is one tablet should be taken as a single dose If sofosbuvir is discontinued, Daclatasvir also get stopped Genotype I: Patient suffered without cirrhosis or with compensated cirrhosis: The recommended dosage of Myhep-Mydekla tablet is one tablet should be taken as a single dose with or without food In decompensated cirrhosis patients: Myhep-Mydekla tablet should be combined with ribavirin as a single dose Genotype III: Patient suffered without cirrhosis or with compensated cirrhosis: The recommended dosage of Myhep-Mydekla is one tablet should be taken as a single dose with or without food In decompensated cirrhosis patients: Myhep-Mydekla tablet should be combined with ribavirin as a single dose The dosage of ribavirin;

7. On basis of body weight & hemoglobin level of patients, dose can be calculated. Less than 75kg: 1000mg of ribavirin; in genotype I or III 600mg of ribavirin as an initial dose and followed as 1000mg/per At least 75 kg: in decompensated cirrhosis 1200mg of ribavirin given as twice daily The safety and efficacy of Mydekla has not been established <18 years Myhepused in ≥12 years or weight of ≥35kg Dosage adjustment in drug interaction; If concurrent use with strong CYP3A inhibitors, the dosage of Mydekla is reduced to 30mg while co administration Concurrent use with moderate CYP3A inducers, the dosage of Mydeklaincreased to 90mg Concomitant use of Mydekla with CYP3A strong inducers should be avoided, it is contraindicated Myhep Mydeklacaused side effects The most common side effects occurred during the therapy; Headache

8. Fatigue Nausea Diarrhea Elevation of lipase Cardiac problems like symptomatic bradycardia Insomnia Pruritus Myalgia Pancytopenia Asthenia Rashes Loss of appetite Irritability Neutropenia Anemia

9. Chills Influenza like symptoms Pyrexia Drug interaction While combining Myhep-Mydekla tablet with strong CYP3A inducers causes loss of virological reaction rate of both products Myhep-Mydekla with HMG CoA reductase inhibitors, this combination leads to cause increasing the exposure of these drugs (statins) CYP3A strong inducers like st Johns wort, rifampin, phenytoin or carbamazepine If Myhep combines with P-gp or BCRP inhibitors leads to cause elevation of sofosbuvir plasma concentration Myhep-Mydekla tablet concomitant with amiodarone causes serious symptomatic bradycardia Myhep-Mydekla tablets concomitant with anti-convulsants, anti-mycobacterials or herbal products like st Johns wort causes decrease in effect of concentration of Myhep-Mydekla tablet Food drug interaction Myhep-Mydekla with herbal product like st. Johns wort causes decreasing the therapeutic effect of Myhep-Mydekla tablet

10. No food drug interaction occurs While using Myhep-Mydekla tablet, caution should be taken Diet should be discussed with consultant Possible contraindications Some contraindications occurs while using Myhep- Mydekla tablets In decompensated cirrhosis, combines with ribavirin contraindicated in pregnancy condition Some anaphylactic reaction occurs if patients are contraindicated to the components present in Myhep-Mydekla tablet Safety measures Myhep-Mydekla tablet causes serious bradycardia while concurrent use with amiodarone, to prevent this condition some alternative medicine is given or discontinue the amiodarone if possible. Counsel the patients about the exposure of bradycardia during the treatment Using Myhep-Mydekla tablet with ribavirin, should not be recommended in pregnancy condition because of producing fetal damage due to ribavirin While taking Myhep-Mydekla , with CYP3A strong inducers causes loss of therapeutic response of Myhep-Mydekla tablet. Avoid this concomitant to reduce the adverse effects

11. Pregnancy and lactation Myhep-Mydekla tablet use in pregnancy, safe to use. The pregnancy category is B1 While combining with ribavirin, not recommended for pregnancy Pregnancy category: X, causes fetal death Breast feeding should not be recommended Storage and handling The storage condition of Myhep-Mydekla tablet should be stored at room temperature below 30oC (86oF) & 20oC and 25oC (68oF and 77oF) respectively Container should be keep away from heat, light and moisture Missed dose Both Myhep-Mydekla tablet are single dose therapy, if patient fails to take the dose of these tablets, must consult the physician and take the dose within the time as per the instruction given by medical practitioner Otherwise the missed dose should be skipped and follow the regular dosing schedule Over dosage

12. The over dosage of Myhep-Mydekla tablet are occurred due to missed dose , if once over dosage occurs the patients must be monitored frequently for endorsement of toxicity and provide safety measures Hemodialysis is a procedure used to eliminate the component from body, sofosbuvir removes with separation coefficient of 54% whereas Daclatasvir is problematic because nearly 99% of drug bounded to human plasma protein CONTACT DETAILS Million Health Pharmaceuticals Old.№131,New.№50,Pedariyar kovil street Seven wells,Chennai-600001.Tamilnadu,India WEBSITE: https://pillsbag.com/products/myhep--mydekla-12- weeks EMAIL: millionhealthpharmaceuticals@gmail.com TRENDY KEYWORDS: Myhep-Mydekla |Myhep-Mydekla tablet |Myhep-Mydekla price in india